Last checked at 
28 Aug 2020 14:38
Maven Income and Growth VCT 4 PLC
Interim Results for the Six Months Ended 30 June 2020 (Unaudited)
The Directors announce the unaudited interim results for the six months ended 30 June 2020.
Highlights
• NAV total return at 30 June 2020 of 142.33p per share
• NAV at 30 June 2020 of 64.73p per share, after payment of the final dividend of 2.00p per share
• Interim dividend of 1.00p per share declared
• 4.5 million invested in 12 new VCT qualifying private and AIM quoted companies, with a further 5 investments completed post the period end
• Follow-on funding provided to 10 portfolio companies as part of their continuing growth plan
• Total gain of £0.94 million generated from realisations of AIM quoted assets
• Realisation of Attraction World for a total return of 1.9 times cost
• Partial realisation of Global Risk Partners for a total return of 2.55 times cost
Overview
During the reporting period, the global economy and financial markets have been significantly impacted by the COVID-19 pandemic, which has created a challenging operating environment for some portfolio companies. The Board and the Manager wish to reassure Shareholders that, since the emergence of the virus in the UK, Maven has acted swiftly to protect Shareholder value, whilst ensuring ongoing compliance with Government guidelines. In response to these unforeseen circumstances, the Manager has taken a small number of provisions against specific private company holdings, in particular those with exposure to consumer facing sectors where the impact of the pandemic has been most pronounced. This resulted in a 9% reduction in NAV per share from 70.91p at the year end to 64.51p at 20 March 2020, as announced on 26 March 2020. However, it is important to highlight that your Company has constructed a highly diversified portfolio with exposure to a wide range of private and AIM quoted companies where, in most cases, trading has remained satisfactory throughout the pandemic. Your Board is aware that regular income distributions remain an important component of Shareholder returns and, following recent exit activity, the Board has declared an interim dividend of 1.00p per share.
The COVID-19 pandemic has had a profound impact on the personal and working lives of most people throughout the UK. Maven responded quickly to the outbreak of coronavirus and, in adherence with Government advice, cancelled all non-essential travel and introduced social distancing measures, with meetings taking place using video conference facilities or by telephone. All Maven employees have been working remotely during the lockdown and the investment team has been in regular dialogue with portfolio companies to offer advice and assistance throughout the crisis. Where possible, investee companies have availed themselves of Government led support, including the Coronavirus Job Retention Scheme and the Coronavirus Business Interruption Loan Scheme. During this period, the Board and the Manager have remained in close contact and will continue to provide updates to Shareholders when appropriate.
It is encouraging to report that the Manager has maintained a good rate of deployment throughout the first half of the financial year, with the addition of twelve new private and AIM quoted company holdings to the portfolio. Several of these new investments were completed during the lockdown period. In these cases, the transaction had been in process since the start of the year and underlying trading was relatively unaffected by the impact of COVID-19. Conversely, a small number of live transactions were terminated in light of increased levels of client churn and a reduction in revenues. New investment activity is continuing cautiously, and face to face meetings are resuming in line with Government guidelines. There are plans for a phased return of staff to Maven's offices, where social distancing measures and enhanced hygiene protocols are already in place.
The Manager remains committed to growing the portfolio through the addition of carefully selected VCT qualifying private and AIM quoted companies from a broad range of sectors. Maven believes that a hybrid strategy, offering the ability to invest across both private equity and AIM, is an important differentiator that helps to build a portfolio with complementary liquidity and return characteristics, as it provides Shareholders with access to a wider range of companies with scope to realise profits at different times. During the period, the AIM portfolio delivered a strong performance, with a number of companies reporting positive trading updates, which resulted in share price appreciation for those investments. This also created the opportunity to lock in gains at a significant premium to the entry price, generating proceeds of £0.94 million, whilst retaining holdings in anticipation of further growth in value.
It is worthwhile noting that, following the active investment strategy that has been pursued over the past few years, your Company now has a large portfolio of young growth orientated businesses that typically operate with a flexible cost base. Many of these companies operate in the software and technology sector and have pre-existing contracts in place with good levels of recurring revenue, which offers some degree of protection from the current economic uncertainty.
The provision of follow-on funding to support portfolio companies that are making tangible commercial progress remains a key component of the investment strategy. The Manager generally adopts a phased or tranched approach and, in certain cases, will make a small initial investment whilst retaining the option to provide further funding, subject to the company achieving agreed commercial milestones. This allows the Manager to monitor progress closely and assess performance before committing additional financial support. Where possible, Maven favours co-investing alongside another VCT house or partner to help further diversify portfolio risk. In terms of new transaction activity, Maven continues to review numerous opportunities across its office network but takes a highly selective approach to investment, only supporting companies that offer a combination of management talent and sustainable growth in revenues. It is also important that the entry price of each new holding offers prospective returns commensurate with the early stage nature of VCT investment.
Realisations are an important element in generating Shareholder returns and help to maintain a programme of regular dividend payments. The Maven team works closely with each unlisted portfolio company that is considering, or is actively engaged in, a sale process, helping to identify the most suitable adviser and potential acquirers that may be willing to pay a premium or strategic price for the business. The current economic uncertainty is, however, likely to result in fewer near term exits, with some sales processes put on hold until market conditions recover.
Dividends
As Shareholders will be aware from recent Annual and Interim Reports, decisions on distributions take into consideration the availability of surplus revenue, the realisation of capital gains, the adequacy of distributable reserves and the VCT qualifying level. These factors are kept under close and regular review by the Board and the Manager, both of whom recognise the importance of tax-free distributions to Shareholders.
In light of the recent realisation activity, the Directors have declared that an interim dividend in respect of the year ending 31 December 2020, of 1.00p per Ordinary Share, will be paid on 2 October 2020 to Shareholders on the register at 4 September 2020. Since the Company's launch, and after receipt of this latest dividend, 78.60p per share will have been distributed in tax-free dividends. It should be noted that the effect of paying dividends is to reduce the NAV of the Company by the total cost of the distribution.
The Directors would like to remind Shareholders that, as the portfolio continues to expand and a greater proportion of holdings are in young companies with growth capital requirements, there will continue to be fluctuations in the quantum and timing of dividend payments. Distributions will be more closely linked to realisation activity and, if larger distributions are required as a consequence of exits, this could result in a commensurate reduction in NAV per share. However, the Board considers this to be a tax-efficient means of returning value to Shareholders, whilst maintaining compliance with the requirements of the VCT legislation.
Dividend Investment Scheme (DIS)
Your Company has in place a DIS, through which Shareholders may elect to have their dividend payments used to apply for new Ordinary Shares issued by the Company under the standing authority granted by Shareholders at AGMs. On 26 March 2020, the Board announced that the DIS had been suspended due to the volatility in financial markets caused by the COVID-19 pandemic, with the payment of the final dividend for the year ended 31 December 2019 on 22 May 2020 being made by either cheque or bank transfer using existing mandate instructions.
The Directors have resolved to re-introduce the DIS with immediate effect. This means that, unless they advise the Company otherwise, those Shareholders who had previously elected to participate in the DIS will revert to receiving new shares with effect from 2 October 2020, being the payment date of the declared interim dividend. Shareholders who have not previously applied to participate in the DIS but wish to do so in respect of the interim dividend payable on 2 October 2020, should ensure that a mandate form, or CREST instruction if appropriate, is received by the Registrar, Link Market Services, prior to the dividend election date of 18 September 2020. Shares issued under the DIS should, subject to an individual Shareholder's particular circumstances, qualify for VCT tax reliefs applicable for the tax year in which they are allotted. The terms & conditions of the scheme, together with a mandate form, are available from the Company's website at: www.mavencp.com/migvct4.
Allotment Update
On 13 November 2019, the Directors of your Company, together with the board of Maven Income and Growth VCT 3 PLC, launched joint Offers for Subscription of new Ordinary Shares for up to £15 million in aggregate (£7.5 million for each company). Your Company's Offer closed on 6 February 2020, fully subscribed.
The allotment of 9,719,959 new Ordinary Shares, in respect of the 2019/20 tax year, was made on 11 February 2020 and 858,029 new Ordinary Shares were allotted in respect of the 2020/21 tax year on 9 July 2020.
This additional liquidity will enable your Company to continue to invest in both private and AIM quoted companies, alongside providing follow-on funding to support existing companies where there is an ongoing business case and commercial traction that merits support. Furthermore, the funds raised will allow your Company to maintain its share buy-back policy, whilst also spreading costs over a wider asset base in line with the objective of maintaining a competitive total expense ratio for the benefit of all Shareholders.
Portfolio Developments
Whilst your Company's portfolio is well diversified, the rapid change in economic activity resulting from the outbreak of COVID-19 has inevitably had an impact on the trading conditions of certain portfolio companies.
As announced on 26 March 2020, the Board and the Manager acted swiftly by taking a small number of protective provisions against those unlisted companies with exposure to consumer facing sectors, which were most immediately affected by the lockdown. Maven continues to work closely with the management teams of all investee companies, taking corrective actions as quickly as possible on a case-by-case basis.
During the period, the oil price was adversely affected by a dispute between Saudi Arabia and Russia, just as the spread of COVID-19 was resulting in a dramatic fall in the global demand for oil. Following an agreement to cut oil production by a record amount, the market has stabilised and the oil price has started to recover. The oil & gas industry is classified as a key sector by both the UK and Scottish Governments and, therefore, portfolio companies servicing this sector have been able to continue to trade throughout the lockdown, with most remaining profitable. Following a number of realisations in recent years, the energy services sector now accounts for less than 8% of the portfolio by value, with all of the remaining assets operating in the service sector and predominantly in areas related to mandatory rather than discretionary spend, which offers some protection in the current economic climate.
On 31 January 2020 the UK formally left the EU and immediately entered into an eleven month transition period, which will end on 31 December 2020. Whilst the full extent of future global trading relationships is still to be determined, as at the date of this report, the portfolio has not been materially affected. The majority of the investee companies have limited direct exposure to the EU, but those that do have been implementing contingency plans to mitigate any potential impact.
Integrated drug discovery service provider BioAscent Discovery has achieved impressive growth since the Maven VCTs first invested in 2018. Over the past two years, the business has recorded 67% compound annual growth in revenue and was recently named top performing outsourcer in the Alantra Pharma Fast 50, which ranks the UK's fastest growing privately owned pharma and pharma service companies. Since investment, BioAscent has expanded its services into complementary chemistry and biology areas and has also grown its client base. BioAscent has also been involved in the UK's response to the outbreak of COVID-19, helping to set up a new testing facility in conjunction with the Scottish Government to scale up virus testing. Despite the challenging operating climate, BioAscent expects to record further growth during 2020.
The first purpose-built facility of Horizon Ceremonies, the Clyde Coast & Garnock Valley, opened in April 2018 and has been steadily building a strong market presence, having been named Best Crematorium in Scotland at the 2019 Scottish Funeral Awards. As part of its growth strategy, Horizon recently acquired two further sites and obtained planning consent for the construction of new crematoria. Building work is now underway at the first location in Cannock, Staffordshire, and is due to commence at the other site in the suburbs of Glasgow during Summer 2020. Two further sites are also now under option, with planning applications submitted. The strategic objective remains to build a portfolio of modern crematoria that provide the highest levels of service and care, alongside the best ethical practice and environmental standards.
In 2016, your Company invested in The GP Service (GPS), which provides a secure end-to-end system that allows patients to consult with a doctor online and to have a prescription dispensed at a local pharmacy. The "on-demand" sector for medical consultations has experienced significant growth over recent years, and this has increased further during the COVID-19 pandemic. GPS remains at the forefront of this market, having secured Care Quality Commission accreditation and using General Medical Council registered doctors, and is the only supplier to have access to NHS Summary Care Records, which has enhanced the service offering. There are now 1,600 pharmacy partners on board and the management team continues to progress a number of significant commercial agreements that could be transformational for the business.
Martel Instruments, a manufacturer and supplier of custom-built compact printers, portable data loggers and display units to the medical, pharmaceutical and other testing and compliance markets has benefitted from a period of strong trading over recent months. The company has proven resilient during the COVID-19 crisis and is experiencing good levels of demand for products from the medical market, which is expected to continue post the end of the lockdown. Martel has a strong order book, is currently operating at full capacity and is forecast to deliver further positive financial performance in 2020.
Visual asset management services group Whiterock continues to make good progress in line with the core objectives identified at the time of the original investment in December 2016. Whiterock's ZynQ360 software solution enables clients to navigate areas of hard-to-access assets such as offshore platforms, refineries or government buildings using 360° photography and video to create a high-definition digital view. The business has developed its technology platform and secured a number of material contracts with international blue-chip clients in the oil & gas and mining sectors, providing a positive endorsement of the ZynQ360 product and its capabilities.
Maven has a dedicated London based AIM VCT team with a deep understanding of the market and long-standing relationships with the local broking community. During the period, the AIM portfolio delivered a positive contribution to the overall performance of your Company. Key contributors to this performance were Avacta, which has reported a steady stream of positive news in relation to the development of its Affimer-based rapid test for COVID-19 for both laboratory and point-of-care settings; and Byotrol, which develops and manufactures antimicrobial and antiviral products for the home, healthcare and personal markets and has experienced exceptional levels of demand since the outbreak of COVID-19. Both companies have performed very well during the period and experienced significant share price appreciation, which facilitated partial realisations of both holdings at a premium to the entry price.
Liquidity Management
The Board and the Manager continue to operate an active liquidity management policy, with the objective of generating income from cash resources held prior to investment. Whilst the Finance Act 2016 introduced the restriction on holding investments in instruments such as treasury bills or other Government-backed securities for liquidity management purposes, it does permit holding certain other listed securities. Based on the Manager's recommendation, the Board has authorised Maven to invest in a small portfolio of listed investment trusts that offer attractive income characteristics. The Manager retains a positive view on these holdings and will continue to consider any other permitted liquidity management investment options that have the potential to generate income alongside the prospect of capital appreciation.
New Investments
During the period, your Company provided development capital to eight VCT qualifying private companies offering interesting growth opportunities:
• HiveHR has developed a software as a service (SaaS) platform that provides real time, responsive and automated employee feedback surveys to enable organisations to better understand and engage with their employees. HiveHR has a diverse customer base that includes Accenture, BrewDog, Hermes, Shop Direct, Tarmac, Travelodge and various NHS and public sector organisations, and retains a high level of recurring revenue. The VCT funding is being used to support the growth of the business as it continues to expand its client base.
• Hublsoft is a data analytics specialist that aims to provide better support for corporate decision makers. Through its SaaS platform, Hublsoft simplifies the analysis of big data using natural language and charts that are simple to interpret and understand. The smart user interface enables the process to be accessible and engaging, making big data more accessible for clients who had previously found it too complex to handle or were heavily reliant on third parties. The VCT funding is being used to support the growth in new markets in the UK and Europe.
• Intilery has developed a digital customer engagement platform that provides a holistic view of a client's marketing activities, as well as using real time data about their customers' behaviour to identify opportunities for enhancing multi- channel marketing campaigns. Personalised interactions and timely reminders are used to create a better customer experience, help improve levels of engagement, enhance customer loyalty and ultimately increase revenues. The VCT funding is being used to expand the sales and marketing team, as well as further develop the product and associated technology.
• Nano Interactive is an advertising technology business that uses online search activity to identify relevant individuals that corporate clients and media agencies should target with their advertising. Nano then places these advertisements in real time, or shortly afterwards, on behalf of clients. The company has a strong client base of blue-chip advertisers, including Microsoft and agency groups such as Omnicom and Publicis. The VCT funding is being used for further product development and to establish a presence in the USA.
• Precursive is a B2B business that provides an easy to use SaaS platform to allow technology and service-based clients to automate their customer onboarding and workforce capacity management. The platform bridges the gap between CRM sales systems and customer success platforms, in order to improve operational efficiency, enhance the experience and reduce client churn. Precursive has built a strong market position on the back of a number of high-quality relationships with companies such as DPD, GoCardless, Google and SES, which also provides good levels of forward revenue visibility. The VCT funding is being used to hire additional development staff, to grow outbound and channel sales and to invest in product development.
• Push Technology is an established technology business that provides client solutions to improve the speed, security and efficiency of real time data transfers. Push has built a strong blue-chip customer base across financial services (including CME and ICAP), e-gaming companies and IOT (Internet of Things), where real-time data is of particularly high importance and value. Push engages with customers through long-term software licenses combined with annual recurring maintenance and support income. The VCT funding is being used to develop the business internationally and to enhance the technology offering.
• Quorum Cyber Security provides managed service security and consulting services to clients across the UK, Europe and the Middle East, where its Clarity platform provides enterprise-grade cyber security at an accessible price point. Quorum has achieved good growth over the past year and is on track to continue this momentum. The VCT funding is being used to invest in sales and marketing, as well as to further develop the relationship with Microsoft, which should enable Quorum to target larger customers in the future.
• The Algorithm People has developed a SaaS platform for the transport and logistics sectors that enables operators to reduce costs by planning the most efficient route and job schedule for their vehicle fleet (including electric vehicles). The My Transport Planner application is delivered through a web browser, thereby reducing any implementation costs or complications. The VCT funding is being used to progress new partnerships and increase market presence.
In addition, four new AIM quoted investments were added to the portfolio:
• Eden Research develops and supplies innovative biopesticide products and natural micro-capsulation technologies to the global crop protection, animal health and consumer products industries. Your Company participated in the £10.1 million fundraising, which completed in March 2020. This investment will enable the company to develop, register and commercialise key new products in categories such as insecticides, formulations and seed treatment, taking a leading position in the rapidly growing sustainable agriculture market.
• Genedrive is a molecular diagnostics company that is developing and commercialising a low cost and simple to use point of need platform for the rapid diagnosis of infectious diseases and use in patient stratification pathogen detection and other indications. Genedrive recently announced the development of a high throughput SARS-CoV-2 test to detect people with the COVID-19 infection. Your Company participated in the £7.0 million placing, which completed in May 2020. The investment is being used to support the developments of the SARS-CoV-2 test and fund product development.
• Intelligent Ultrasound is a global leader in ultrasound training through simulation, which has expanded into the development of AI software to support doctors and sonographers in clinical and ultrasound scanning. Your Company participated in the £5.2 million fundraising, which completed in April 2020. The investment is being used to support existing and new product development, as well as strengthening the balance sheet and providing general working capital.
• Trackwise Designs is a leading provider of specialist interconnector products, manufacturing printed circuit technology for use across multiple sectors and applications. Your Company participated in the £5.9 million fundraising, which completed in March 2020, providing important growth capital to enable the business to further develop its proprietary technology.
The following investments have been completed during the reporting period:
Purchases |
Date |
Sector | Investment cost £'000 |
Website |
New unlisted | ||||
HiveHR Limited | February 2020 | Software & computer services | 300 | www.hive.hr.com |
(employment services) | ||||
Hublsoft Group Limited | June 2020 | Software & computer services | 800 | www.hublsoft.com |
(financial services) | ||||
Intilery.com Limited | April 2020 | Software & computer services | 75 | www.intilery.com |
(marketing) | ||||
Nano Interactive Group Limited | March 2020 | Software & computer services | 625 | www.nanointeractive.com |
(advertising) | ||||
Precursive Limited | March 2020 | Software & computer services | 750 | www.precursive.com |
(professional/employment | ||||
services) | ||||
Push Technology Limited | March 2020 | Software & computer services | 525 | www.pushtechnology.com |
(consumer services) | ||||
Quorum Cyber Security Limited | June 2020 | Software & computer services | 500 | www.quorumcyber.com |
(cyber security) | ||||
The Algorithm People Limited | May 2020 | Software & computer services | 300 | www.thealgorithmpeople.co.uk |
(transport) | ||||
Total new unlisted | 3,875 | |||
Follow-on unlisted | ||||
e.fundamentals (Group) Limited | April 2020 | Software & computer services | 333 | www.efundamentals.com |
(marketing) | ||||
Growth Capital Ventures Limited | June 2020 | Investment companies | 63 | www.growthcapitalventures.co.uk |
Horizon Cremation Limited | May 2020 | Support Services (consumer services) | 400 | www.horizoncremation.co.uk |
Lending Works Limited | February 2020 | Software & computer services | 42 | www.lendingworks.co.uk |
(financial services) | ||||
Life's Great Group Limited (trading | March 2020 | Software & computer services | 43 | www.mojomortgages.com |
as Mojo Mortgages) | (financial services) | |||
QikServe Limited | March 2020 | Software & computer services | 120 | www.qikserve.com |
(hospitality) | ||||
Relative Insight Limited | June 2020 | Software & computer services | 600 | www.relativeinsight.com |
(marketing) | ||||
The GP Service (UK) Limited | May 2020 | Health | 163 | www.thegpservice.co.uk |
Total follow-on unlisted | 1,764 | |||
Total unlisted | 5,639 |
Purchases |
Date |
Sector | Investment cost £'000 |
Website |
New quoted | ||||
Eden Research PLC | March 2020 | Chemicals | 102 | www.edenresearch.com |
Genedrive PLC | May 2020 | Pharmaceuticals & biotechnology | 25 | www.genedriveplc.com |
Intelligent Ultrasound Group PLC | May 2020 | Software & computer services (healthcare) | 400 | www.intelligentultrasound.com |
Trackwise Designs PLC | March 2020 | Electronics & electrical equipment | 63 | www.trackwise.co.uk |
Total new quoted | 590 | |||
Follow-on quoted | ||||
C4X Discovery Holdings PLC | May 2020 | Pharmaceuticals & biotechnology | 47 | www.c4xdiscovery.com |
Diurnal Group PLC | March 2020 | Pharmaceuticals & biotechnology | 61 | www.diurnal.co.uk |
Total follow-on quoted | 108 | |||
Total quoted | 698 | |||
Total investments | 6,337 |
At the period end, the portfolio stood at 111 unlisted and quoted investments, at a total cost of £59.27 million.
Realisations
In February 2020, your Company realised its holding in Attraction World, one of the UK's largest theme park and attraction ticket specialists. Since Maven originally backed the MBO of the business in December 2010, Attraction World has enabled millions of customers to pre-book tickets for 5,000 experiences in over 50 countries, including amusement parks, sightseeing tours, theatre shows and experience days. In 2016, the company made the strategic acquisition of Day Out With The Kids, the UK's biggest website and online community for family attractions and children's activities. The realisation, via a secondary buyout led by the CEO, generated a total return of 1.9 times cost over the life of the investment.
In June 2020, the partial sale of the investment in Global Risk Partners (GRP) completed. Your Company originally invested in GRP in 2013, participating in a syndicate to back a highly experienced management team to pursue a buy & build strategy in the specialty insurance and reinsurance markets. Since launch, the business has achieved significant scale, having completed and successfully integrated 59 acquisitions, with the enlarged business now achieving annual gross written premium of almost £800 million. Following a competitive process, an offer for the business was received from a US private equity buyer, with a partial exit completing conditionally in February 2020. Regulatory approval for the transaction was subsequently granted and the sale concluded shortly before the period end, generating a total return of 2.55 times cost, and the proceeds will be distributed to your Company in due course.
During the period, your Company partially sold a number of holdings in the AIM portfolio where positive newsflow had resulted in share price appreciation, creating the opportunity to realise profits. This active trading strategy helped to generate a total realised gain of £0.94 million.
The table below gives details of all realisations achieved during the reporting period:
Sales |
Year first invested |
Complete/ partial exit | Cost of shares disposed of £'000 | Value at 31 December 2019 £'000 |
Sales proceeds £'000 |
Realised gain/(loss) £'000 | Gain/(loss) over 31 December 2019 value £'000 |
Unlisted Attraction World Holding Limited Other unlisted investments |
2010 |
Complete |
355 - |
415 3 |
417 3 |
62 3 |
2 - |
Total unlisted |
|
| 355 | 418 | 420 | 65 | 2 |
Quoted |
|
|
|
|
|
|
|
Avacta Group PLC | 2018 | Partial | 226 | 232 | 863 | 637 | 631 |
Byotrol PLC | 2017 | Partial | 55 | 56 | 210 | 155 | 154 |
Diaceutics PLC | 2019 | Partial | 78 | 102 | 121 | 43 | 19 |
Eden Research PLC | 2020 | Partial | 19 | 19 | 25 | 6 | 6 |
Genedrive PLC | 2020 | Partial | 10 | 2 | 23 | 13 | 21 |
Ideagen PLC | 2015 | Partial | 17 | 99 | 103 | 86 | 4 |
(formerly Datum PLC) |
|
|
|
|
|
|
|
Total quoted |
|
| 405 | 510 | 1,345 | 940 | 835 |
|
|
|
|
|
|
|
|
Total sales |
|
| 760 | 928 | 1,765 | 1,005 | 837 |
Material Developments Since the Period End
Since 30 June 2020, one new private company holding has been added to the portfolio:
• GEN InCode is a provider of clinical genetic tests, which use AI bioinformatics and a globally recognised clinical evidence base to provide predictive analysis of a patient's risk in order to determine which medical treatments and procedures will have the optimal outcome for patients. The company has developed novel specific genetic markers to help doctors to create targeted treatment and prevention plans for patients. The VCT funding is being used to expand its presence in the European market and to enter the US, which has been identified as a key market for future growth.
In addition, four new AIM quoted companies were added to the portfolio:
• AFC Energy is a global leader in hydrogen power generation technologies. It has a proven fuel cell technology, which it is commercialising through its Hydrogen Power (H-Power) product, an off-grid electric vehicle charging system that is run on hydrogen and produces no emissions. Your Company participated in the £31.6 million fundraising, which completed in July 2020. The investment is being used to facilitate the manufacture of the H-Power fuel cell for deployment in the next 12-24 months, to employ manufacturing, engineering and commercial staff to support the expansion of target markets (electric vehicles and construction), and to fund further product development.
• DeepMatter is a technology company that has developed an integrated software, hardware and machine learning enabled platform, DigitalGlassware, which operates across the research and process development sectors. The solution enables users to translate chemistry processes into computer code, making it easier to record, reproduce and share. Your Company participated in the £2.1 million fundraising, which completed in July 2020. The investment is being used to strengthen the balance sheet and to provide funding to invest in sales, marketing and distribution support to facilitate a growing market presence and market share.
• Feedback is a specialist medical imaging technology company that has developed Bleepa, an innovative medical communication app that allows radiologists, clinicians and medical researchers to view and discuss high quality images securely on mobile devices, directly from the hospital source, thereby improving workflow efficiency. Your company participated in the £5.0 million fundraising, which completed in July 2020. The investment will be used to enhance the sales force targeting NHS Trusts and other key strategic partners, to further product development and accelerate international expansion.
• Velocys designs and develops fuel technology and now licences its proprietary reactor and catalyst technology for the conversion of biomass and household waste into jet fuel. Your Company participated in the £21 million fundraising, which completed in July 2020. The investment is being used to support product development and commercialisation, and to provide working capital to ensure the company's intellectual property remains protected.
Principal and Emerging Risks and Uncertainties
The principal and emerging risks and uncertainties facing the Company were set out in full in the Strategic Report contained within the 2019 Annual Report, and are the risks associated with investment in small and medium sized unlisted and AIM/AQSE quoted companies which, by their nature, carry a higher level of risk and are subject to lower liquidity than investments in larger quoted companies. The valuation of investee companies may be affected by economic conditions, the credit environment and other risks including legislation, regulation, adherence to VCT qualifying rules and the effectiveness of the internal controls operated by the Company and the Manager. These risks and procedures are reviewed regularly by the Audit and Risk Committees and reported to your Board. The Board has confirmed that all tests, including the criteria for VCT qualifying status, continue to be monitored and met.
During the period under review, the COVID-19 pandemic developed from being an emerging risk to a principal risk that had implications for the Company, the Manager, investee companies and both the UK and global economies. The Board and the Manager have sought to identify all of the individual associated risks that could impact on the Company and the steps that are required to mitigate them. These have been recorded in separate risk registers that are maintained by the Company and the Manager, and will be reviewed on a regular basis as the situation continues to evolve.
Share Buy-backs
Shareholders have given the Board authority to buy back shares for cancellation or to be held in treasury, subject always to such transactions being in the best interests of Shareholders. It is intended that, subject to market conditions, available liquidity and the maintenance of the Company's VCT status, shares will continue to be bought back at prices representing a discount of up to 15% of the prevailing NAV per share. During the period under review, 730,000 shares were bought back at a total cost of £480,000.
Regulatory Update
Following the outbreak of the COVID-19 pandemic, there have been a number of regulatory developments that are intended to assist and support companies through this crisis. The Corporate Insolvency and Governance Act will temporarily suspend parts of insolvency law to support directors to continue trading through the emergency without the threat of personal liability for wrongful trading and to protect companies from creditor action. In addition, Company Law and other legislation will be amended to provide companies with temporary easements on company filings and the holding of AGMs.
The Financial Conduct Authority (FCA) has recognised that fund managers and auditors could face challenges in preparing financial information as a result of the pandemic and have announced an extension to the filing deadlines for annual and interim reports. Your Company, however, does not expect to have to take advantage of these extended filing deadlines.
The FCA has also published detailed information setting out its expectations during the crisis. The FCA expects firms to take reasonable steps to ensure that they are prepared to meet the challenges presented by coronavirus in order to maintain business continuity. Firms are encouraged to ensure that they are managing their financial resilience and liquidity, and to report to the FCA if they believe they will face difficulties. The FCA has also set out its high-level expectations on the application of firms' systems and controls for combatting and preventing financial crime, including client identity verification.
On 27 March 2020, the International Private Equity and Venture Capital Valuation (IPEV) Guidelines Board issued special valuation guidance to assist managers who are applying the IPEV Valuation Guidelines to their 31 March 2020 portfolios. The Guidelines were last updated in 2018 and are the prevailing framework for fair value information in the private equity and venture capital industry. In the current global crisis, it is vitally important that information continues to flow in a timely and consistent manner, and the special valuation guidance reinforces key valuation principles in order to ensure the robustness of information making its way to investors and other stakeholders.
Outlook
Notwithstanding the unforeseen difficulties presented by the COVID-19 pandemic, your Company remains well positioned, benefitting from a diverse portfolio of younger companies seeking to achieve significant growth and scale, together with a number of more established and mature private and AIM quoted investments. The strategy for the second half of the financial year will remain focused on cautiously expanding and further developing the portfolio. In particular, the Manager will be seeking out those growth companies that have strong recurring or contractual revenues, or which operate an online business model, or are generally more defensive to the market and trading conditions experienced in the first half of the year.
On behalf of the Board
Maven Capital Partners UK LLP
Secretary
28 August 2020
Summary of Investment Changes
For the six months ended 30 June 2020
| Valuation 31 December 2019 £'000 % | Net investment/ (disinvestment) £'000 | Appreciation/ (depreciation) £'000 | Valuation 30 June 2020 £'000 % | ||
Unlisted investments |
|
|
|
|
|
|
Equities | 29,090 | 39.8 | 4,981 | (3,183) | 30,888 | 42.7 |
Loan stock | 15,726 | 21.5 | 238 | (1,519) | 14,445 | 19.9 |
| 44,816 | 61.3 | 5,219 | (4,702) | 45,333 | 62.6 |
AIM/AQSE investments Equities |
4,937 |
6.7 |
(647) |
1,180 |
5,470 |
7.5 |
Listed investments Investment trusts |
4,435 |
6.1 |
- |
(699) |
3,736 |
5.1 |
Total investments | 54,188 | 74.1 | 4,572 | (4,221) | 54,539 | 75.2 |
Other net assets | 18,935 | 25.9 | (914) | - | 18,021 | 24.8 |
Net assets | 73,123 | 100.0 | 3,658 | (4,221) | 72,560 | 100.0 |
Investment Portfolio Summary
As at 30 June 2020
Investment |
Valuation £'000 |
Cost £'000 |
% of total assets |
% of equity held | % of equity held by other clients1 |
Unlisted |
|
|
|
|
|
Horizon Cremation Limited | 2,463 | 2,463 | 3.4 | 12.9 | 39.7 |
BioAscent Discovery Limited | 1,776 | 1,532 | 2.4 | 26.1 | 13.9 |
Whiterock Group Limited | 1,753 | 1,014 | 2.4 | 13.0 | 17.0 |
Vodat Communications Group Limited | 1,717 | 1,240 | 2.4 | 7.1 | 19.8 |
CatTech International Limited | 1,642 | 1,115 | 2.3 | 8.4 | 21.6 |
The GP Service (UK) Limited | 1,622 | 1,597 | 2.2 | 19.2 | 32.1 |
Maven Co-invest Endeavour Limited Partnership | 1,563 | 909 | 2.2 | 13.3 | 86.7 |
(invested in Global Risk Partners)2 |
|
|
|
|
|
Glacier Energy Services Holdings Limited | 1,540 | 1,540 | 2.1 | 6.0 | 21.7 |
Rockar 2016 Limited (trading as Rockar) | 1,442 | 1,374 | 2.0 | 6.5 | 9.2 |
CB Technology Group Limited | 1,405 | 1,097 | 1.9 | 19.6 | 59.3 |
Bright Network (UK) Limited | 1,383 | 1,383 | 1.9 | 12.1 | 26.2 |
Martel Instruments Holdings Limited | 1,332 | 1,120 | 1.8 | 14.7 | 29.6 |
QikServe Limited | 1,255 | 1,674 | 1.7 | 7.6 | 8.2 |
Contego Solutions Limited (trading as NorthRow) | 1,201 | 1,201 | 1.7 | 7.8 | 10.5 |
HCS Control Systems Group Limited | 1,201 | 1,201 | 1.7 | 10.7 | 25.8 |
ebb3 Limited | 1,186 | 1,307 | 1.6 | 23.3 | 35.3 |
RMEC Group Limited | 1,084 | 782 | 1.5 | 4.8 | 45.3 |
Flow UK Holdings Limited | 1,047 | 1,047 | 1.4 | 12.7 | 22.3 |
Boiler Plan (UK) Limited | 1,000 | 1,000 | 1.4 | 24.0 | 32.5 |
Relative Insight Limited | 1,000 | 1,000 | 1.4 | 5.3 | 24.0 |
WaterBear Education Limited | 987 | 987 | 1.4 | 22.4 | 21.3 |
Ensco 969 Limited (trading as DPP) | 983 | 1,823 | 1.4 | 7.4 | 27.1 |
Filtered Technologies Limited | 950 | 950 | 1.3 | 10.1 | 16.5 |
Life's Great Group Limited (trading as Mojo | 949 | 939 | 1.3 | 12.0 | 23,8 |
Mortgages) |
|
|
|
|
|
Curo Compensation Limited | 846 | 1,117 | 1.2 | 12.1 | 6.9 |
Hublsoft Group Limited | 800 | 800 | 1.1 | 12.5 | 18.7 |
Precursive Limited | 750 | 750 | 1.0 | 6.5 | 15.1 |
TC Communications Holdings Limited | 734 | 958 | 1.0 | 10.7 | 19.3 |
Optoscribe Limited | 726 | 726 | 1.0 | 5.1 | 4.6 |
eSafe Global Limited | 653 | 871 | 0.9 | 16.7 | 15.4 |
Growth Capital Ventures Limited | 650 | 639 | 0.9 | 12.8 | 30.3 |
Maven Capital (Marlow) Limited | 650 | 650 | 0.9 | - | 100.0 |
AVID Technology Group Limited | 635 | 635 | 0.9 | 4.4 | 5.6 |
Nano Interactive Group Limited | 625 | 625 | 0.9 | 3.7 | 11.2 |
Delio Limited | 533 | 533 | 0.7 | 3.6 | 9.9 |
Investment Portfolio Summary (Continued)
As at 30 June 2020
Investment |
Valuation £'000 |
Cost £'000 |
% of total assets |
% of equity held | % of equity held by other clients1 |
Unlisted (continued) |
|
|
|
|
|
Push Technology Limited | 525 | 525 | 0.7 | 2.8 | 8.5 |
Quorum Cyber Security Limited | 500 | 500 | 0.7 | 8.7 | 12.3 |
ADC Biotechnology Limited | 485 | 1,094 | 0.7 | 7.4 | 11.1 |
Symphonic Software Limited | 480 | 480 | 0.7 | 5.7 | 8.6 |
e.fundamentals (Group) Limited | 467 | 467 | 0.6 | 3.8 | 7.1 |
CODILINK UK Limited (trading as Coniq) | 400 | 400 | 0.6 | 1.1 | 3.8 |
ISN Solutions Group Limited | 348 | 467 | 0.5 | 7.8 | 47.2 |
Shortbite Limited (trading as DigitalBridge) | 325 | 325 | 0.4 | 2.8 | 17.9 |
HiveHR Limited | 300 | 300 | 0.4 | 5.2 | 33.7 |
The Algorithm People Limited | 300 | 300 | 0.4 | 9.7 | 16.3 |
R&M Engineering Group Limited | 268 | 1,087 | 0.4 | 13.4 | 57.2 |
Altra Consultants Limited | 250 | 250 | 0.3 | 4.2 | 55.8 |
GradTouch Limited | 150 | 200 | 0.2 | 2.9 | 32.6 |
Honcho Markets Limited | 129 | 129 | 0.2 | 2.4 | 22.3 |
Fathom Systems Group Limited | 121 | 1,066 | 0.2 | 12.7 | 47.3 |
Space Student Living Limited | 76 | 51 | 0.1 | 19.3 | 60.8 |
Intilery.com Limited | 75 | 75 | 0.1 | 3.3 | 23.1 |
FLXG Scotland Limited | 51 | 339 | 0.1 | 3.2 | 11.1 |
(formerly Flexlife Group Limited) |
|
|
|
|
|
Other unlisted investments | - | 4,148 | - |
|
|
Total unlisted | 45,333 | 50,802 | 62.6 |
|
|
Quoted |
|
|
|
|
|
Ideagen PLC (formerly Datum PLC) | 906 | 166 | 1.3 | 0.2 | 0.9 |
Pelatro PLC | 596 | 496 | 0.9 | 2.8 | - |
Creo Medical Group PLC | 580 | 497 | 0.8 | 0.2 | - |
Intelligent Ultrasound Group PLC | 419 | 400 | 0.6 | 1.7 | 0.7 |
Byotrol PLC | 366 | 208 | 0.5 | 1.4 | 0.7 |
Diaceutics PLC | 310 | 163 | 0.4 | 0.3 | 0.3 |
MaxCyte Inc | 279 | 250 | 0.4 | 0.3 | 0.3 |
Avacta Group PLC | 232 | 33 | 0.3 | 0.1 | 0.1 |
The Panoply Holdings PLC | 218 | 212 | 0.3 | 0.5 | - |
Scancell Holdings PLC | 213 | 205 | 0.3 | 1.1 | - |
Oxford Metrics PLC (formerly OMG PLC) | 168 | 80 | 0.2 | 0.2 | - |
C4X Discovery Holdings PLC | 152 | 160 | 0.2 | 0.8 | 1.4 |
KRM22 PLC | 141 | 220 | 0.2 | 1.6 | - |
Eden Research PLC | 108 | 83 | 0.1 | 0.4 | 1.1 |
Investment Portfolio Summary (Continued)
As at 30 June 2020
Investment |
Valuation £'000 |
Cost £'000 |
% of total assets |
% of equity held | % of equity held by other clients1 |
Quoted (continued) |
|
|
|
|
|
Vectura Group PLC | 100 | 100 | 0.1 | - | - |
Diurnal Group PLC | 98 | 100 | 0.1 | 0.3 | 0.5 |
Faron Pharmaceuticals PLC | 92 | 70 | 0.1 | 0.1 | 0.2 |
Angle PLC | 89 | 92 | 0.1 | 0.1 | 0.1 |
Hardide PLC | 75 | 122 | 0.1 | 0.4 | 0.3 |
Trakwise Designs PLC | 65 | 63 | 0.1 | 0.4 | 1.1 |
Cello Health PLC | 59 | 55 | 0.1 | 0.1 | 0.4 |
Osirium Technologies PLC | 52 | 100 | 0.1 | 1.5 | 4.4 |
Access Intelligence PLC | 47 | 42 | 0.1 | - | 0.2 |
Seen PLC (formerly Entertainment AI PLC) | 42 | 75 | 0.1 | - | 1.4 |
Vianet Group PLC (formerly Brulines Group PLC) | 35 | 49 | - | 0.1 | 1.4 |
Genedrive PLC | 19 | 15 | - | - | 0.1 |
The Ince Group PLC (formerly Gordon Dadds PLC) | 6 | 172 | - | 0.1 | - |
Deltex Medical Group PLC | 3 | 33 | - | 0.1 | - |
Other quoted investments | - | 149 | - |
|
|
Total quoted | 5,470 | 4,410 | 7.5 |
|
|
Private equity investment trusts |
|
|
|
|
|
HgCapital Trust PLC | 469 | 428 | 0.7 | 0.1 | 0.1 |
Princess Private Equity Holding Limited | 383 | 391 | 0.6 | 0.1 | 0.1 |
Apax Global Alpha Limited | 362 | 384 | 0.5 | 0.1 | 0.1 |
BMO Private Equity Trust PLC (formerly F&C | 312 | 343 | 0.4 | 0.2 | 0.3 |
Private Equity Trust PLC) |
|
|
|
|
|
HarbourVest Global Private Equity Limited | 279 | 250 | 0.4 | - | 0.1 |
ICG Enterprise Trust PLC | 220 | 250 | 0.3 | - | 0.1 |
Standard Life Private Equity Trust PLC | 171 | 190 | 0.2 | - | 0.1 |
Pantheon International PLC | 168 | 180 | 0.2 | - | 0.1 |
Total private equity investment trusts | 2,364 | 2,416 | 3.3 |
|
|
Real estate investment trusts |
|
|
|
|
|
Target Healthcare REIT Limited | 192 | 199 | 0.3 | 0.1 | - |
Regional REIT Limited | 184 | 265 | 0.2 | 0.1 | 0.1 |
Custodian REIT PLC | 109 | 140 | 0.1 | - | - |
Schroder REIT Limited | 104 | 206 | 0.1 | 0.1 | - |
Total real estate investment trusts | 589 | 810 | 0.7 |
|
|
Investment Portfolio Summary (Continued)
As at 30 June 2020
Investment |
Valuation £'000 |
Cost £'000 |
% of total assets |
% of equity held | % of equity held by other clients1 |
Fixed income investment trusts TwentyFour Income Fund Limited Alcentra European Floating Rate Income Fund Limited |
175 167 |
196 191 |
0.3 0.2 |
0.1 0.1 |
- - |
Total fixed income investment trusts | 342 | 387 | 0.5 |
|
|
Infrastructure investment trusts |
|
|
|
|
|
3i Infrastructure PLC | 118 | 118 | 0.2 | - | - |
The Renewables Infrastructure Group Limited | 116 | 122 | 0.2 | - | - |
HICL Infrastructure Company Limited | 105 | 104 | 0.1 | - | - |
International Public Partnerships Limited | 102 | 102 | 0.1 | - | - |
Total infrastructure investment trusts | 441 | 446 | 0.6 |
|
|
|
|
|
|
|
|
Total investments | 54,539 | 59,271 | 75.2 |
|
|
1 Other clients of Maven Capital Partners UK LLP.
2 Managed by Penta Capital LLP of which Steven Scott, a Director of the Company, is a partner.
Income Statement
For the six months ended 30 June 2020
| Six months ended 30 June 2020 (unaudited) | Six months ended 30 June 2019 (unaudited) | Year ended 31 December 2019 (audited) | ||||||
| Revenue £'000 | Capital £'000 | Total £'000 | Revenue £'000 | Capital £'000 | Total £'000 | Revenue £'000 | Capital £'000 | Total £'000 |
(Losses) / gains on investments | - | (4,221) | (4,221) | - | 775 | 775 | - | 1,497 | 1,497 |
Income from investments | 691 | - | 691 | 818 | - | 818 | 1,509 | - | 1,509 |
Other income | 16 | - | 16 | 48 | - | 48 | 81 | - | 81 |
Investment management fees | (182) | (728) | (910) | (164) | (657) | (821) | (315) | (1,260) | (1,575) |
Other expenses | (228) | - | (228) | (142) | - | (142) | (337) | - | (337) |
Net return on ordinary activities before taxation | 297 | (4,949) | (4,652) | 560 | 118 | 678 | 938 | 237 | 1,175 |
Tax on ordinary activities |
(25) |
25 |
- |
(50) |
50 |
- |
(162) |
162 |
- |
Return attributable to Equity Shareholders | 272 | (4,924) | (4,652) | 510 | 168 | 678 | 776 | 399 | 1,175 |
Earnings per share (pence) |
0.25 |
(4.46) |
(4.21) |
0.67 |
0.22 |
0.89 |
1.01 |
0.52 |
1.53 |
All gains and losses are recognised in the Income Statement.
All items in the above statement are derived from continuing operations. The Company has only one class of business and one reportable segment, the results of which are set out in the Income Statement and Balance Sheet. The Company derives its income from investments made in shares, securities and bank deposits.
There are no potentially dilutive capital instruments in issue and, therefore, no diluted earnings per share figures are relevant. The basic and diluted earnings per share are, therefore, identical.
The accompanying Notes are an integral part of the Financial Statements.
Statement Of Changes In Equity
For the six months ended 30 June 2020
Six months ended 30 June 2020 (unaudited)
|
Share capital £'000 | Share premium account £'000 | Capital reserve realised £'000 | Capital reserve unrealised £'000 | Special distributable reserve £'000 | Capital redemption reserve £'000 |
Revenue reserve £'000 |
Total £'000 |
At 31 December 2019 Net return | 10,311 - | 16,526 - | (11,818) 302 | 494 (5,226) | 55,995 - | 51 - | 1,564 272 | 73,123 (4,652) |
Share premium cancellation costs | - | (38) | - | - | - | - | - | (38) |
Merger costs | - | (14) | - | - | - | - | - | (14) |
Dividends paid | - | - | (1,401) | - | - | - | (841) | (2,242) |
Repurchase and cancellation of shares | (73) | - | - | - | (480) | 73 | - | (480) |
Net proceeds of share issue | 972 | 5,891 | - | - | - | - | - | 6,863 |
At 30 June 2020 | 11,210 | 22,365 | (12,917) | (4,732) | 55,515 | 124 | 995 | 72,560 |
Six months ended 30 June 2019 (unaudited)
|
Share capital £'000 | Share premium account £'000 | Capital reserve realised £'000 | Capital reserve unrealised £'000 | Special distributable reserve £'000 | Capital redemption reserve £'000 |
Revenue reserve £'000 |
Total £'000 |
At 31 December 2018 Net return | 7,657 - | 48,568 - | (9,020) 835 | (1,186) (667) | 7,675 - | 472 - | 788 510 | 54,954 678 |
Repurchase and cancellation of shares | (73) | - | - | - | (474) | 73 | - | (474) |
At 30 June 2019 | 7,584 | 48,568 | (8,185) | (1,853) | 7,201 | 545 | 1,298 | 55,158 |
Year ended 31 December 2019 (audited)
|
Share capital £'000 | Share premium account £'000 | Capital reserve realised £'000 | Capital reserve unrealised £'000 | Special distributable reserve £'000 | Capital redemption reserve £'000 |
Revenue reserve £'000 |
Total £'000 |
At 31 December 2018 Net return | 7,657 - | 48,568 - | (9,020) (1,281) | (1,186) 1,680 | 7,675 - | 472 - | 788 776 | 54,954 1,175 |
Cancellation of share premium account | - | (48,562) | - | - | 48,562 | - | - | - |
Cancellation of capital redemption reserve | - | - | - | - | 544 | (544) | - | - |
Share premium cancellation costs | - | (9) | - | - | - | - | - | (9) |
Dividends paid | - | - | (1,517) | - | - | - | - | (1,517) |
Repurchase and cancellation of shares | (123) | - | - | - | (786) | 123 | - | (786) |
Issue of shares on merger | 2,758 | 16,427 | - | - | - | - | - | 19,185 |
Net proceeds of DIS issue | 19 | 102 | - | - | - | - | - | 121 |
At 31 December 2019 | 10,311 | 16,526 | (11,818) | 494 | 55,995 | 51 | 1,564 | 73,123 |
The accompanying Notes are an integral part of the Financial Statements.
Balance Sheet
As at 30 June 2020
| 30 June 2020 (unaudited) £'000 | 30 June 2019 (unaudited) £'000 | 31 December 2019 (audited) £'000 |
Fixed assets Investments at fair value through profit or loss |
54,539 |
35,018 |
54,188 |
Current assets Debtors Cash |
673 17,401 |
529 19,797 |
708 18,402 |
| 18,074 | 20,326 | 19,110 |
Creditors |
|
|
|
Amounts falling due within one year | (53) | (186) | (175) |
Net current assets | 18,021 | 20,140 | 18,935 |
Net assets | 72,560 | 55,158 | 73,123 |
Capital and reserves |
|
|
|
Called up share capital | 11,210 | 7,584 | 10,311 |
Share premium account | 22,365 | 48,568 | 16,526 |
Capital reserve - realised | (12,917) | (8,185) | (11,818) |
Capital reserve - unrealised | (4,732) | (1,853) | 494 |
Special distributable reserve | 55,515 | 7,201 | 55,995 |
Capital redemption reserve | 124 | 545 | 51 |
Revenue reserve | 995 | 1,298 | 1,564 |
Net assets attributable to Ordinary Shareholders | 72,560 | 55,158 | 73,123 |
|
|
|
|
Net asset value per Ordinary Share (pence) | 64.73 | 72.73 | 70.91 |
The Financial Statements were approved by the Board of Directors on 28 August 2020 and were signed on its behalf by:
Peter Linthwaite
Director
The accompanying Notes are an integral part of the Financial Statements.
Cash Flow Statement
For the six months ended 30 June 2020
| Six months ended 30 June 2020 (unaudited) £'000 | Six months ended 30 June 2019 (unaudited) £'000 | Year ended 31 December 2019 (audited) £'000 |
Net cash flows from operating activities
Cash flows from investing activities Purchase of investments Sale of investments | (579)
(6,337) 1,826 | 173
(3,927) 3,472 | (120)
(23,503) 4,478 |
Net cash flows from investing activities | (4,511) | (455) | (19,025) |
Cash flows from financing activities |
|
|
|
Equity dividends paid | (2,242) | - | (1,517) |
Issue of Ordinary Shares | 6,863 | - | 121 |
Merger costs | (14) | - | - |
Issue of Ordinary Shares - merger | - | - | 19,185 |
Share premium cancellation costs | (38) | - | (9) |
Repurchase of Ordinary Shares | (480) | (474) | (786) |
Net cash flows from financing activities | 4,089 | (474) | 16,994 |
|
|
|
|
Net decrease in cash | (1,001) | (756) | (2,151) |
Cash at beginning of period | 18,402 | 20,553 | 20,553 |
Cash at end of period | 17,401 | 19,797 | 18,402 |
The accompanying Notes are an integral part of the Financial Statements.
Notes To The Financial Statements
1. Accounting policies
The financial information for the six months ended 30 June 2020 and the six months ended 30 June 2019 comprises non-statutory accounts within the meaning of S435 of the Companies Act 2006. The financial information contained in this report has been prepared on the basis of the accounting policies set out in the Annual Report and Financial Statements for the year ended 31 December 2019, which have been filed at Companies House and contained an Auditor's Report that was not qualified and did not contain a statement under S498(2) or S498(3) of the Companies Act 2006.
2. Reserves
Share premium account
The share premium account represents the premium above nominal value received by the Company on issuing share net of issue costs. This reserve is non distributable.
Capital reserves
Gains or losses on investments realised in the year that have been recognised in the Income Statement are transferred to the capital reserve realised account on disposal. Furthermore, any prior unrealised gains or losses on such investments are transferred from the capital reserve unrealised account to the capital reserve realised account on disposal.
Increases and decreases in the fair value of investments are recognised in the Income Statement and are then transferred to the capital reserve unrealised account. The capital reserve realised account also represents capital dividends, capital investment management fees and the tax effect of capital items. This reserve is distributable.
Special distributable reserve
The total cost to the Company of the repurchase and cancellation of shares is represented in the special distributable reserve. This reserve is distributable.
Capital redemption reserve
The nominal value of shares repurchased and cancelled is represented in the capital redemption reserve. This reserve is non distributable.
Revenue reserve
The revenue reserve represents accumulated profits retained by the Company that have not been distributed to Shareholders as a dividend. This reserve is distributable.
3. Return per Ordinary Share
| Six months ended 30 June 2020 |
The returns per share have been based on the following figures: Weighted average number of Ordinary Shares
Revenue return Capital return |
110,419,876
£272,000 (£4,924,000) |
Total return | (£4,652,000) |
Directors' Responsibility Statement
The Directors confirm that, to the best of their knowledge:
• the Financial Statements for the six months ended 30 June 2020 have been prepared in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland;
• the Interim Management Report includes a fair review of the information required by DTR 4.2.7R in relation to the indication of important events during the first six months, and of the principal risks and uncertainties facing the Company during the second six months, of the year ending 31 December 2020; and
• the Interim Management Report includes adequate disclosure of the information required by DTR 4.2.8R in relation to related party transactions and any changes therein.
Other information
A full copy of the Interim Report and Financial Statements will be printed and issued to Shareholders. Copies of this announcement will be available to the public at the registered office of the Company at Kintyre House, 205 West George Street, Glasgow G2 2LW; at the office of the Manager, Maven Capital Partners UK LLP, 5th Floor, 1-2 Royal Exchange Buildings, London EC3V 3LF; and, in due course, on the Company's website at www.mavencp.com/migvct4.
Neither the content of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.
By order of the Board
Maven Capital Partners UK LLP
Secretary
28 August 2020